IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Long-Term Efficacy and Tolerability of a Fixed-Dose Combination of Antihypertensive Agents An Open-Label Surveillance Study in China
Wu, Yiqun1,2; Hu, Yonghua1,2; Tang, Xun1,2; He, Liu1,2; Ren, Tao1,2; Tao, Qiushan1,2; Qin, Xueying1,2; Sun, Ningling3; Wang, Hongyi3; Cao, Weihua1,2; Wu, Tao1,2; Zhan, Siyan1,2; Wang, Jin4; Chen, Weihua4; Li, Liming1,2
刊名CLINICAL DRUG INVESTIGATION
2011
31期:11页:769-777
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Pharmacology & Pharmacy
研究领域[WOS]Pharmacology & Pharmacy
关键词[WOS]BLOOD-PRESSURE ; HYPERTENSIVE PATIENTS ; HYDROCHLOROTHIAZIDE ; AMLODIPINE ; METAANALYSIS ; MULTICENTER ; PREVENTION ; MANAGEMENT ; ADHERENCE ; ATENOLOL
英文摘要

Background: A fixed-dose combination (FDC) of four compounds, hydrochlorothiazide 12.5 mg, triamterene 12.5 mg, dihydralazine 12.5 mg and reserpine 0.1 mg (HTDR), is widely used as an antihypertensive treatment in China. Although HTDR has been used in China for more than 30 years, there have been few comprehensive evaluations of this treatment.

Objective: The aim of this study was to investigate the long-term efficacy and tolerability of HTDR in Chinese patients with essential hypertension.

Methods: This was a 36-month, community-based, open-label surveillance study, conducted in the Huangpu District (Shanghai, China). The study was based in local primary healthcare settings. Subjects were recruited if they had essential hypertension, were aged >= 35 years at the time of enrolment, were expected to remain in the area for 3 years, and were able to provide informed consent. Patients who had secondary hypertension, myocardial infarction or stroke within 6 months of screening, impaired renal or hepatic function, history of cardiomyopathy or chronic heart failure, or were pregnant or lactating were excluded. HTDR was administered as one or two tablets per day in the morning. If necessary, additional hydrochlorothiazide was added. Blood pressure (BP) was measured at baseline and throughout the 36-month surveillance period every 3 months. Biochemical indicators (e.g. fasting blood glucose, plasma lipid parameters, plasma sodium and potassium, plasma uric acid and serum creatinine) were also measured, and adverse events were noted. BP reductions and the rate at which patients achieved BP targets (systolic BP [SBP] < 140 mmHg and diastolic BP [DBP] < 90 mmHg) throughout the period were determined. Subgroup analyses by sex and age were also conducted.

Results: A total of 1529 patients (550 male, 979 female; mean age 65.7 years) entered the study. After the 36-month treatment period, 93.1% of patients had achieved the SBP target, 97.9% had achieved the DBP target, and 92.1% had achieved both. The mean decreases in SBP and DBP were 15.3 mmHg and 9.9 mmHg, respectively. Overall, 127 adverse events in 119 patients (7.8%) occurred during the follow-up period, most of which were mild to moderate. Plasma lipid profiles were improved after 24 months of treatment. In addition, a significant increase in plasma potassium and a significant reduction in plasma uric acid were seen.

Conclusion: HTDR was found to have good long-term efficacy and tolerability in Chinese patients with essential hypertension.

语种英语
WOS记录号WOS:000297185900003
项目编号2001BAF03B02 ; 2006BAI01A03-(16)
资助机构Chinese Science &amp ; Technology (ST) Ministry
引用统计
被引频次:1[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/56835
专题北京大学第二临床医学院
北京大学医学部管理机构_医学部
北京大学公共卫生学院_流行病与卫生统计学系
北京大学公共卫生学院_公共卫生学院
北京大学临床肿瘤学院_麻醉科
北京大学公共卫生学院_学院办公室
作者单位1.Peking Univ, Hlth Sci Ctr, Dept Epidemiol & Biostat, Beijing 100191, Peoples R China
2.Peking Univ, Minist Educ, Key Lab Epidemiol, Beijing 100871, Peoples R China
3.Peking Univ, Peoples Hosp, Cardiovasc Dept, Beijing 100871, Peoples R China
4.Community Care Ctr, Shanghai, Peoples R China
推荐引用方式
GB/T 7714
Wu, Yiqun,Hu, Yonghua,Tang, Xun,et al. Long-Term Efficacy and Tolerability of a Fixed-Dose Combination of Antihypertensive Agents An Open-Label Surveillance Study in China[J]. CLINICAL DRUG INVESTIGATION,2011,31(11):769-777.
APA Wu, Yiqun.,Hu, Yonghua.,Tang, Xun.,He, Liu.,Ren, Tao.,...&Li, Liming.(2011).Long-Term Efficacy and Tolerability of a Fixed-Dose Combination of Antihypertensive Agents An Open-Label Surveillance Study in China.CLINICAL DRUG INVESTIGATION,31(11),769-777.
MLA Wu, Yiqun,et al."Long-Term Efficacy and Tolerability of a Fixed-Dose Combination of Antihypertensive Agents An Open-Label Surveillance Study in China".CLINICAL DRUG INVESTIGATION 31.11(2011):769-777.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wu, Yiqun]的文章
[Hu, Yonghua]的文章
[Tang, Xun]的文章
百度学术
百度学术中相似的文章
[Wu, Yiqun]的文章
[Hu, Yonghua]的文章
[Tang, Xun]的文章
必应学术
必应学术中相似的文章
[Wu, Yiqun]的文章
[Hu, Yonghua]的文章
[Tang, Xun]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。